Paradigm Peptides Was the Warm-Up. The Tissue Grey Market Is the Real Target.

On July 30, 2026, a federal judge in the Northern District of Indiana sentenced Matthew Kawa to 70 months in prison. His sister, Jennifer Stechkober, got 16 months. Their company, Paradigm Peptides, sold peptides, SARMs, and HCG to roughly 54,000 customers in all 50 states and 80 countries between 2019 and 2024, pulling in about $5 million before the FDA and DOJ shut it down. Kawa also owes a $5 million money judgment on top of restitution.

The facts are ugly. Kawa admitted he never tested the SARM products he sold. When prosecutors tested six of his testosterone-mimicking compounds, all six contained actual testosterone. One customer, Dan Murphy, developed steroid-induced psychosis: insomnia, paranoid delusions, cystic acne, suicidal ideation, confirmed by a lab as triggered by a contaminated product he’d bought believing it was research-grade and safe. FDA sent Paradigm warning letters in 2020 and 2022. Kawa ignored both and kept telling customers his products were FDA-licensed, domestically made, and pharmaceutical-grade. None of that was true. Judge Cristal Brisco told him he’d left “an incredible trail of harm” after ignoring “numerous warnings.”

That is peptides. Read the fact pattern again and swap out the word “peptide” for the word “tissue.” Interstate distribution to tens of thousands of buyers. False claims about testing and FDA status. Ignored warning letters. Documented patient harm. Total absence of quality testing. Nothing about that pattern is unique to bodybuilding supplements. It’s the exact operating model of a large slice of the human tissue and exosome market selling into orthopedic clinics, IV lounges, and med spas right now, and the legal groundwork to prosecute it the same way is already built.

Human cells, tissues, and cellular and tissue-based products, HCT/Ps in FDA’s language, are governed by 21 CFR Part 1271. That regulation draws a hard line between two categories, and almost every seller in the grey market is standing on the wrong side of it while marketing as if they’re on the right one.

A product gets the light-touch pathway, regulation solely under section 361 of the Public Health Service Act, only if it clears all four criteria in 21 CFR 1271.10(a): minimal manipulation, homologous use, no combination with another article beyond water, crystalloids, or a storage agent, and no systemic effect dependent on living cell metabolism unless it’s autologous, going to a first- or second-degree blood relative, or for reproductive use. Clear all four and the requirement is registration and listing plus current good tissue practice. Fail even one and the product is a drug or biological product under section 351, requiring an IND for clinical study and a Biologics License Application to market it at all, on top of full current Good Manufacturing Practice under 21 CFR 210/211 and 21 CFR 600 through 680.

Most of what’s being sold as “regenerative” injectable tissue product fails this test on its face. FDA has already said, in writing, that culturing cells, expanding them, and isolating exosomes from conditioned media counts as more than minimal manipulation. Using umbilical cord or amniotic tissue for anti-inflammatory signaling, wound healing, or systemic infusion is not the tissue’s original function in the donor, which means it fails homologous use too. That’s two of four criteria gone before you even get to the third and fourth. FDA has stated plainly, and repeated in a wave of recent warning letters, that it has approved zero exosome products for injection, systemic use, or implantation. Zero. Not “not yet fully cleared.” Zero.

This isn’t a hypothetical enforcement gap. FDA has been building the record for years, and the pace has picked up.

Back in 2019, FDA warned Stemell, Inc. over its umbilical cord blood and umbilical cord products, citing deficient donor eligibility practices, inadequate environmental monitoring, unvalidated manufacturing processes, and insufficient aseptic procedures. The agency’s own language: the deviations “pose a risk that the products may be contaminated with viruses or microorganisms or have other serious product quality defects.” That’s FDA, not a plaintiff’s lawyer, describing the downside of skipping cGMP.

On December 1, 2025, FDA cited Celularity over Interfyl, a placental connective tissue matrix, for marketing beyond homologous use into orthopedic applications. Celularity is a well-funded, publicly traded, cGMP-compliant manufacturer distributing through a legitimate surgical supply partner. If FDA is willing to write up a company with real compliance infrastructure over indication creep, the exposure facing an operation with no cGMP, no registration, and no testing at all is not a close call.

On February 11, 2026, FDA hit Dynamic Stem Cell Therapy for converting umbilical cord tissue from a conduit into an injectable form, destroying the tissue’s physical integrity and failing minimal manipulation, then marketing the injectable for cardiovascular disease and arthritis, failing homologous use on top of it. Same letter flagged exosome products for “multiple reports of serious adverse events.” Between late 2024 and early 2026, FDA also sent warning letters to Evolutionary Biologics, Chara Biologics, New Life Medical Services, and Platinum Biologics, all for unapproved new drug claims and failure to validate sterility on exosome products.

Layer the cGMP and ISO angle on top of the legal classification, because they’re connected, not separate problems. Once a product fails the 361 test, it’s a drug or biologic, and sterile injectable manufacturing at that point means an ISO Class 5 primary engineering control inside an ISO 7 or better buffer room, the standard baked into USP <797> for high-risk sterile compounding and referenced throughout FDA’s aseptic processing guidance. That is not paperwork. It’s a real facility, validated equipment, environmental monitoring, and a quality system, running seven figures a year before a single vial ships. A garage, a rented suite, or an overseas contract shop with no ISO classification and no third-party identity, potency, sterility, and endotoxin testing is not a shortcut version of that facility. It’s the absence of it, and it’s exactly the gap FDA keeps citing by name.

For years, clinics selling unapproved cell and tissue products argued this was the practice of medicine, not drug manufacturing, and therefore outside FDA’s reach. That argument is dead.

The Eleventh Circuit ruled against U.S. Stem Cell Clinic in 2021, holding that stromal vascular fraction, marketed as “fat stem cells,” is an unapproved drug subject to FDA authority. The Ninth Circuit reached the identical conclusion in 2024 against California Stem Cell Treatment Center and Cell Surgical Network, rejecting the surgical-procedure exemption because the processing involved goes well past what a conventional low-risk surgery involves. On October 14, 2025, the Supreme Court denied certiorari, letting the Ninth Circuit ruling stand nationwide. FDA’s authority to treat these products as unapproved drugs is now settled law in two circuits with no split for the Supreme Court to resolve. The “this is medicine, not manufacturing” defense doctors have leaned on for a decade no longer holds.

Put the pieces next to each other. DOJ was willing to send someone to federal prison for 70 months over interstate sale of unapproved peptides where the documented harm was psychiatric and dermatologic. Tissue and exosome products go directly into joints, veins, and IV lines. The realistic harm profile there, sepsis, embolism, disease transmission from inadequately screened donor tissue, is more severe and more provable in front of a jury than acne and insomnia. Every element that made the Paradigm Peptides case prosecutable maps directly onto tissue: interstate distribution of the product, false claims about FDA status and testing, no independent verification of what the vial contains, and warning letters that got ignored. The only thing standing between the current warning letter volume and a Kawa-style criminal case is DOJ picking the file it considers clean enough to bring. Given how many letters have gone out since 2024, that file is being assembled right now.

Physicians and clinic owners buying this product need to hear this part directly: administering it is not a safe harbor. Injecting or infusing a product you know, or willfully avoided finding out, is unapproved, unregistered, and untested exposes you personally under the FDCA’s misbranding and adulteration provisions, in front of your state medical board, and in a malpractice claim your carrier will likely decline to cover because the product itself was illegal to use in the first place. “FDA-registered facility” on a supplier’s sell sheet describes where the material sat, not whether the product is approved, and that exact phrasing has already shown up as a cited violation in FDA warning letters. If a supplier has no current Tissue Establishment Registration listing, no third-party sterility and identity testing on the specific lot in your hand, and no documented donor eligibility screening under 21 CFR 1271 Subpart C, you are not buying a tissue product. You’re buying the next exhibit in a federal case.

For those of us building through the 351(a) BLA pathway the way the statute requires, full cGMP, ISO-classified suites, third-party release testing on every lot, registered and listed establishments, years of donor and manufacturing qualification data before a product ever reaches a patient, the grey market is not merely a patient safety problem. It’s a competitive one. It lets an unregistered operator undercut every legitimate manufacturer on price by skipping every cost that keeps patients safe. Kawa’s sentencing wasn’t the end of a story about peptides. It was the opening paragraph of the next one, and this time the product going into the vial isn’t a supplement. It’s a piece of someone.

Andrew Jonathan Hillman from Dallas Texas www.andrew-Hillman.com